2-氯-3-甲氧基吡啶 | 52605-96-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氯-3-甲氧基吡啶
• 中文别名: 3-甲氧基-2-氯吡啶
• 英文名称: 2-chloro-3-methoxypyridine
• CAS: 52605-96-6
• 化学式: C₆H₆ClNO
• mdl: MFCD03426022
• 分子量: 143.573
• InChiKey: CCVNZKGBNUPYPG-UHFFFAOYSA-N

物化性质

• 熔点：
  90-92°C
• 沸点：
  210.6±20.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会分解，目前没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保持贮藏器密封，并将其存放在阴凉、干燥的地方。同时，确保工作环境中具备良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Chloro-3-methoxypyridine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Chloro-3-methoxypyridine
Ingredient name:
CAS number: 52605-96-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H6ClNO
Molecular weight: 143.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法：

向三颈烧瓶中依次加入2-氯-3-羟基吡啶（5.0克，39.0毫摩尔）、N,N-二甲基甲酰胺（60毫升）和甲醇钠（2.30克，43.0毫摩尔）。在室温下搅拌反应物20分钟后，缓慢加入甲基碘（8.20克，58.0毫摩尔），并在室温下继续搅拌40分钟。

然后向混合液中加入120毫升水，并用乙酸乙酯（100毫升×3次）萃取。合并有机相，分别用水（100毫升×2次）和饱和盐水（100毫升）洗涤后，再用无水硫酸钠干燥并过滤。

最后，将滤液旋转蒸发浓缩，得到黄色液体产物——2-氯-3-甲氧基吡啶。

反应信息

• 作为反应物：
  描述：

  2-氯-3-甲氧基吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 溴 、 一水合肼 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 76.5h， 生成 8-methoxy-3-oxo-2-(2-trimethylsilanyl-ethoxymethyl)-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridine-7-carboxylic acid methyl ester
  参考文献：
  名称：

  [EN] PHARMACEUTICAL COMPOUNDS
  [FR] COMPOSÉS PHARMACEUTIQUES

  摘要：

  公开号：

  WO2011033265A8
• 作为产物：
  描述：

  3-甲氧基吡啶 在 盐酸 、 potassium permanganate 作用下， 以 水 为溶剂， 以10.20 g的产率得到2-氯-3-甲氧基吡啶
  参考文献：
  名称：

  一种卤代含氮不饱和环烃的制备方法

  摘要：

  本发明公开了一种卤代含氮不饱和环烃的制备方法，步骤为：（1）将含氮不饱和环烃溶解于盐酸或氢溴酸中，加入氧化剂，使反应体系进行卤代反应，反应过程中定时取样检测，当检测到目标产物一卤化物的质量占比为反应体系内的总有机物的70%‑95%时，向反应体系内加入终止剂终止反应，便得到含有含氮不饱和环烃的料液；（2）向料液加入有机溶剂进行萃取，萃取后得到有机相，将有机相降温使其析出固体物或蒸馏有机相除去溶剂得到液体产物，所得固体物或液体产物为卤代含氮不饱和环烃。该方法很好的解决了含氮不饱和环烃过卤代化反应的问题。

  公开号：

  CN107954913A

文献信息

• Room-Temperature Suzuki-Miyaura Coupling of Heteroaryl Chlorides and Tosylates
  作者：Junfeng Yang、Sijia Liu、Jian-Feng Zheng、Jianrong Steve Zhou

  DOI：10.1002/ejoc.201200918

  日期：2012.11

  Suzuki–Miyaura coupling of heteroaryls is an important method for the preparation of compound libraries for medicinal chemistry and materials research. Although many catalysts have been developed, none of them have been generally applicable to the coupling reactions of heteroaryl chlorides and tosylates at room temperature. We discovered that a catalyst combination of Pd(OAc)2 and XPhos (2-dicyclohexylphosphanyl-2′

  杂芳基的 Suzuki-Miyaura 偶联是制备用于药物化学和材料研究的化合物库的重要方法。尽管已经开发了许多催化剂，但它们都没有普遍适用于杂芳基氯与甲苯磺酸酯在室温下的偶联反应。我们发现 Pd(OAc)2 和 XPhos（2-二环己基膦酰基-2',4',6'-三异丙基联苯）的催化剂组合可以有效地催化这些偶联。除了催化剂的选择，在含水醇溶剂中使用氢氧化物碱对于快速偶联也是必不可少的。这些条件促进了活性催化剂（XPhos）Pd0 的快速释放，并加速了催化循环中的金属转移。大多数杂芳基氯（31 个实例）和甲苯磺酸盐（17 个实例）的主要家族在室温下在几分钟到几小时内达到完全转化。该方法可以很容易地扩大规模以进行克级合成。此外，我们检查了整个反应中偶联伙伴的相对反应性。富电子杂芳基氯化物和甲苯磺酸盐的反应速度比缺电子杂芳基化合物慢，顺序为吲哚、吡咯呋喃、噻吩>吡啶。类似地，缺电子芳基硼酸的反应
• D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Tsai Guochuan Emil

  公开号：US20190112289A1

  公开（公告）日：2019-04-18

  The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independently, is aryl, heteroaryl, aralkyl, H, or absent; each of L 1 and L 2 , independently, is a moiety selected from O, CH 2 , C═O, C 2-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, —((CH 2 ) n —W)—, wherein n=0, 1, 2, 3, 4, or 5, and W is O or S, or absent; and when L 2 is absent, Z is aryl or heteroaryl fused with B C. Also provided in the present invention is a method for inhibiting, treating and/or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐，其中：A、B、C、D 和 E 中的每一个独立地是 C、N、N—H、O、S 或不存在 是单键或双键；X、Y 和 Z 中的每一个独立地是芳基、杂环芳基、芳基烷基、H 或不存在；L 1 和 L 2 中的每一个独立地是从 O、CH 2 、C═O、C 2-10 烷基、C 2-10 烯基、C 2-10 炔基、—((CH 2 ) n —W)— 中选择的基团，其中 n=0、1、2、3、4 或 5，W 是 O 或 S，或不存在；当 L 2 不存在时，Z 是与 B 相融合的芳基或杂环芳基。本发明还提供了一种用于抑制、治疗和/或减少神经精神障碍风险的方法，包括向需要的受试者施用包含式（I）化合物的组合物。
• [EN] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES<br/>[FR] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL-N-ARYL-BENZAMIDES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE CYTOKINES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2005090333A1

  公开（公告）日：2005-09-29

  Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

  公开的化合物式(I)，可以抑制与炎症过程有关的细胞因子的产生，因此可用于治疗涉及炎症的疾病和病理状况，如慢性炎症性疾病。还公开了制备这些化合物的方法以及包含这些化合物的药物组合物。
• [EN] AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF<br/>[FR] COMPOSÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE HPK1 ET LEUR UTILISATION
  申请人：BEIGENE LTD

  公开号：WO2021032148A1

  公开（公告）日：2021-02-25

  Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

  本文揭示了一种式(I)的氨基吡嗪化合物，或其立体异构体，或其药学上可接受的盐，以及包含它们的药物组合物。还公开了利用本文所披露的化合物治疗HPK1相关疾病或疾病的方法。
• Studies on pyridoxine and pyridoxal analogs—I
  作者：Dietrich Heinert、Arthur E. Martell

  DOI：10.1016/s0040-4020(01)82610-7

  日期：1958.1

  reported. The preparation of the thio-semicarbazones of the aldehydes, as potential tuberculostatic agents, and of 3-hydroxy-4-hydroxymethylpyridine and 3-methoxy-4-hydroxymethylpyridine as pyridoxine analogs, are described.

  报道了3-羟基吡啶-2-醛，3-甲氧基吡啶-2-醛，3-羟基吡啶-4-醛，3-甲氧基吡啶-4-醛及其衍生物和一些新的中间体的制备，纯化和性质。描述了作为潜在的抗结核剂的醛的硫代半咔唑和作为吡pyr醇类似物的3-羟基-4-羟基甲基吡啶和3-甲氧基-4-羟基甲基吡啶的制备。